Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 153

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 153
---
 obtained from
the patients prior to the provision of the various treatments. Customers are not entitled to enjoy the relevant services until outstanding
amounts have been settled pursuant to the relevant contract. Sales to individual consumers did not vary significantly and none of the
customers contribute more than 10% of NewGenIvf’s revenue for the years ended December 31, 2024 and 2023.

In addition to significant
customers using NewGenIvf’s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
utilize the access to the freezing and storage facility and other relatively insignificant services, such as check-ups services, blood
test services and other minor services (the latter category of customers are referred to as “consultation customers”).

In addition to significant
customers using NewGenIvf’s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
only use its relatively insignificant services, such as check-ups services, blood test services and other minor services (the latter
category of customers are referred to as “consultation customers”).

Sales and Marketing

For the years ended
December 31, 2024 and 2023, NewGenIvf promoted brand awareness through its sales teams and, in many cases, through cooperating
with third-party agencies and partners.

NewGenIvf’s sales teams have broad experience in fertility services
and are responsible for identifying potential clients and managing the overall sales process. NewGenIvf’s sales team primarily relies
on social media marketing, word-of-mouth referrals, recognition of its brand, printed advertisements and marketing events. NewGenIvf spends
marketing expenses on placing advertisements through popular social media platforms, maintaining the official website of NewGenIvf and
sending information through its official accounts on social media platforms.

Supply and Procurement

NewGenIvf’s procurement
is mainly for medications, laboratory media and reagents, laboratory consumables, and blood test reagents. As of December 31, 2023,
there was one supplier that individually contributed more than 10% of the Group’s trade payable, accounting for 30.6% of the Group’s
trade payables. For both the years ended December 31, 2024 and 2023, no vendor contributed more than 10% of total direct cost of
the Group. NewGenIvf’s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable suppliers.